A review on triple-negative breast cancer and its potential treatment

Abstract

Triple-negative breast cancer is defined as breast cancer that lacks estrogen, progesterone, and the human epidermal growth factor receptor 2. (TNBC). This malignancy accounts for 15–20 percent of all breast cancers and is of particular interest for study because of its clinically problematic low treatment response and highly invasive features. Due to the lack of particular treatment options for TNBC, conventional therapy such as adjuvant and neoadjuvant therapy, surgery, immunotherapy, and radiation therapy are frequently used. The focus of this review is to provide information related to TNBC diagnosis and survival rate, biomarkers, different signaling pathways as well as current and investigation therapies, prognosis, and some advanced research about drugs and therapies. Researchers working in the area may find the data offered in this publication useful in obtaining general and specific information to increase their understanding of TNBC and provide appropriate disease management in the future.